What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (five amino acids) that acts as a growth hormone secretagogue — meaning it stimulates the pituitary gland to produce and release growth hormone (GH). It was first developed in the 1990s by Novo Nordisk and has since become one of the most studied GH-releasing peptides.

What sets ipamorelin apart from earlier secretagogues like GHRP-6 and GHRP-2 is its selectivity. While those peptides can elevate cortisol, prolactin, and appetite along with GH, ipamorelin produces a much cleaner GH pulse with far fewer off-target effects.

Ipamorelin works by binding to the ghrelin receptor (GHS-R1a) in the pituitary gland. Here's the cascade:

• Ghrelin receptor activation: Ipamorelin mimics ghrelin's action on pituitary somatotroph cells, triggering GH release
• Pulsatile GH secretion: Unlike exogenous HGH, ipamorelin preserves the body's natural pulsatile GH release pattern
• IGF-1 elevation: Increased GH stimulates the liver to produce Insulin-like Growth Factor 1 (IGF-1), which mediates many of GH's downstream effects
• Minimal cortisol impact: Studies confirm ipamorelin does not significantly affect ACTH or cortisol levels even at high doses
• No prolactin elevation: Unlike GHRP-2 and GHRP-6, ipamorelin has negligible effects on prolactin

This selective profile makes ipamorelin ideal for researchers studying GH effects in isolation without confounding hormonal variables.

Research has identified several potential benefits of ipamorelin-induced GH elevation:

• Improved body composition: Elevated GH and IGF-1 promote lipolysis (fat breakdown) and lean mass preservation
• Enhanced recovery: GH plays a key role in tissue repair, collagen synthesis, and bone healing
• Better sleep quality: GH secretion is closely tied to deep sleep stages; ipamorelin may enhance sleep architecture
• Anti-aging potential: GH decline (somatopause) is a hallmark of aging; restoring physiological levels may support skin, bone, and cognitive health
• Bone density support: Studies show GH elevation from ipamorelin increases bone mineral content in animal models
• Joint and connective tissue health: Elevated IGF-1 supports collagen synthesis throughout the body

Ipamorelin is administered via subcutaneous injection. Common research dosage protocols include:

• Standard dose: 200–300 mcg per injection, 2–3 times daily
• Timing: Typically administered on an empty stomach — morning, post-workout, and before bed are common windows
• Cycle length: Research protocols often run 8–12 weeks, followed by a washout period
• Stacking: Frequently combined with CJC-1295 (no DAC) to amplify and sustain GH release

Reconstitution: Reconstitute lyophilized powder with bacteriostatic water. Store refrigerated and use within 4 weeks.

Dosages are based on research literature. Individual protocols should be supervised by a qualified healthcare provider.

Ipamorelin has one of the cleanest safety profiles among GH secretagogues. Reported side effects include:

• Mild headache: Occasionally reported, especially when starting a protocol
• Injection site irritation: Minor redness or swelling at the injection site
• Water retention: Mild and transient, related to GH-mediated fluid shifts
• Tingling or numbness: Rare; associated with elevated GH levels

Importantly, ipamorelin does not cause the hunger spikes associated with GHRP-6 or the cortisol elevations seen with hexarelin. Long-term safety data in humans remains limited, and ipamorelin is banned by WADA.

Quality matters when sourcing growth hormone secretagogues. We recommend Ascension Peptides for ipamorelin based on:

• 99%+ purity verified via HPLC and mass spectrometry
• Publicly available COAs for every product batch
• Proper cold-chain handling ensuring peptide integrity during shipping
• Competitive pricing with fast US-based fulfillment

Ascension Peptides is a DailyVial affiliate partner that meets our standards for purity, testing transparency, and reliability.